114 related articles for article (PubMed ID: 15528975)
1. Investigation of HMN-176 anticancer activity in human tumor specimens in vitro and the effects of HMN-176 on differential gene expression.
Medina-Gundrum L; Cerna C; Gomez L; Izbicka E
Invest New Drugs; 2005 Jan; 23(1):3-9. PubMed ID: 15528975
[TBL] [Abstract][Full Text] [Related]
2. AMD473 (ZD0473) exhibits marked in vitro anticancer activity in human tumor specimens taken directly from patients.
Medina-Gundrum L; Cerna C; Gomez LR; Yochmowitz M; Weitman S
Anticancer Drugs; 2003 Apr; 14(4):275-80. PubMed ID: 12679731
[TBL] [Abstract][Full Text] [Related]
3. HMN-176, an active metabolite of the synthetic antitumor agent HMN-214, restores chemosensitivity to multidrug-resistant cells by targeting the transcription factor NF-Y.
Tanaka H; Ohshima N; Ikenoya M; Komori K; Katoh F; Hidaka H
Cancer Res; 2003 Oct; 63(20):6942-7. PubMed ID: 14583495
[TBL] [Abstract][Full Text] [Related]
4. Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro.
Eckardt JR; Burris HA; Kuhn JG; Bissery MC; Klink-Alakl M; Clark GM; Von Hoff DD
J Natl Cancer Inst; 1994 Jan; 86(1):30-3. PubMed ID: 8271279
[TBL] [Abstract][Full Text] [Related]
5. Activity of oxaliplatin against human tumor colony-forming units.
Raymond E; Lawrence R; Izbicka E; Faivre S; Von Hoff DD
Clin Cancer Res; 1998 Apr; 4(4):1021-9. PubMed ID: 9563898
[TBL] [Abstract][Full Text] [Related]
6. Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.
Petit T; Izbicka E; Lawrence RA; Bishop WR; Weitman S; Von Hoff DD
Ann Oncol; 1999 Apr; 10(4):449-53. PubMed ID: 10370788
[TBL] [Abstract][Full Text] [Related]
7. In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176.
Takagi M; Honmura T; Watanabe S; Yamaguchi R; Nogawa M; Nishimura I; Katoh F; Matsuda M; Hidaka H
Invest New Drugs; 2003 Nov; 21(4):387-99. PubMed ID: 14586206
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units.
Hidalgo M; Izbicka E; Eckhardt SG; MacDonald JR; Cerna C; Gomez L; Rowinsky EK; Weitman SD; Von Hoff DD
Anticancer Drugs; 1999 Oct; 10(9):837-44. PubMed ID: 10587294
[TBL] [Abstract][Full Text] [Related]
9. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.
Burris HA; Hanauske AR; Johnson RK; Marshall MH; Kuhn JG; Hilsenbeck SG; Von Hoff DD
J Natl Cancer Inst; 1992 Dec; 84(23):1816-20. PubMed ID: 1331485
[TBL] [Abstract][Full Text] [Related]
10. A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors.
Garland LL; Taylor C; Pilkington DL; Cohen JL; Von Hoff DD
Clin Cancer Res; 2006 Sep; 12(17):5182-9. PubMed ID: 16951237
[TBL] [Abstract][Full Text] [Related]
11. Activity of temozolomide against human tumor colony-forming units.
Raymond E; Izbicka E; Soda H; Gerson SL; Dugan M; Von Hoff DD
Clin Cancer Res; 1997 Oct; 3(10):1769-74. PubMed ID: 9815562
[TBL] [Abstract][Full Text] [Related]
12. Activity of DMP 840, a new bis-naphthalimide, on primary human tumor colony-forming units.
Cobb PW; Degen DR; Clark GM; Chen SF; Kuhn JG; Gross JL; Kirshenbaum MR; Sun JH; Burris HA; Von Hoff DD
J Natl Cancer Inst; 1994 Oct; 86(19):1462-5. PubMed ID: 8089865
[TBL] [Abstract][Full Text] [Related]
13. Activity of MKT 077, a rhodacyanine dye, against human tumor colony-forming units.
Petit T; Izbicka E; Lawrence RA; Nalin C; Weitman SD; Von Hoff DD
Anticancer Drugs; 1999 Mar; 10(3):309-15. PubMed ID: 10327038
[TBL] [Abstract][Full Text] [Related]
14. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
15. MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27.
Pai HC; Kumar S; Shen CC; Liou JP; Pan SL; Teng CM
PLoS One; 2015; 10(4):e0123819. PubMed ID: 25874627
[TBL] [Abstract][Full Text] [Related]
16. A gene expression database for the molecular pharmacology of cancer.
Scherf U; Ross DT; Waltham M; Smith LH; Lee JK; Tanabe L; Kohn KW; Reinhold WC; Myers TG; Andrews DT; Scudiero DA; Eisen MB; Sausville EA; Pommier Y; Botstein D; Brown PO; Weinstein JN
Nat Genet; 2000 Mar; 24(3):236-44. PubMed ID: 10700175
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations.
Györffy B; Surowiak P; Kiesslich O; Denkert C; Schäfer R; Dietel M; Lage H
Int J Cancer; 2006 Apr; 118(7):1699-712. PubMed ID: 16217747
[TBL] [Abstract][Full Text] [Related]
18. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
[TBL] [Abstract][Full Text] [Related]
19. Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay.
Britten CD; Izbicka E; Hilsenbeck S; Lawrence R; Davidson K; Cerna C; Gomez L; Rowinsky EK; Weitman S; Von Hoff DD
Cancer Chemother Pharmacol; 1999; 44(2):105-10. PubMed ID: 10412943
[TBL] [Abstract][Full Text] [Related]
20. Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units.
Siu LL; Von Hoff DD; Rephaeli A; Izbicka E; Cerna C; Gomez L; Rowinsky EK; Eckhardt SG
Invest New Drugs; 1998; 16(2):113-9. PubMed ID: 9848574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
